Clinical trial
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01559363 is registered in ClinicalTrials.gov with Kadmon, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Lead sponsor
- Kadmon, a Sanofi Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 11, 2012
- Completion date
- February 8, 2019
- Enrollment
- 69 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.